Clonazepam

Controlled drug under the Misuse of Drugs Act 1975.³² Requires prescription for lawful possession and is subject to restrictions on manufacturing and distribution.citation needed

The current list does not mark clonazepam as prohibited under section 5.

The official regulation classifies clonazepam in Verzeichnis b; this classification is not the same as Swissmedic dispensing category B.

Current official law controls clonazepam while permitting regulated prescription medical use in United States.

The instrument, dated 28 May 2026, is in force and contains the Schedule 4 definition and the clonazepam entry.

ANVISA Portaria 344/98 expressly lists Clonazepam as item 21 in Lista B1, whose heading makes its substances subject to Notificação de Receita B. The same regulation defines psychotropic notifications as blue (cor azul). Anvisa's current controlled-substances page identifies Portaria 344/98 as the governing regulation and RDC nº 1.036/2026 as the latest update listed; that RDC updates Annex I without changing clonazepam's B1 designation. Clonazepam has the official B1 / blue Notificação de Receita designation and is subject to controlled prescription use rather than absolute prohibition.

Current official law controls clonazepam while permitting regulated prescription medical use in Canada.

Regulation 463/2013's current text is effective 25 June 2026. Its List 7 expressly includes Klonazepam and defines List 7 as Convention Schedule IV psychotropics plus other psychotropics for which medicines must be dispensed in a pharmacy on prescription or requisition without a blue stripe. Act 167/1998 § 4 generally requires a handling permit, while § 5(2) expressly allows doctors to prescribe List 7 preparations, pharmacists to prepare and dispense them on a medical prescription, and individuals to acquire, keep and use them for their own needs on the basis of a prescription. The SÚKL database record updated 27 August 2026 identifies RIVOTRIL registration 21/225/73-A/C, active ingredient KLONAZEPAM, and Rx dispensing. Unauthorized supply/manufacture/import/export or other provision can fall under Criminal Code § 283 (one to five years at the base level, with aggravated ranges of two to ten, five to twelve, or eight to eighteen years). Unauthorized personal possession above the statutory “greater than small” amount is covered by § 284 (up to two years, or six months to five years in a greater extent, or two to eight years in a considerable extent). Act 167/1998 § 39(2)(e) treats unauthorized personal possession of another addictive substance in a small amount as an administrative offence punishable by a fine up to CZK 50,000; the cited statutes do not provide a numerical clonazepam threshold, so none is inferred here. For legal persons or businesses handling without a required permit, § 36(1)(a) and § 37(1)(c) provide an administrative offence and a possible fine up to CZK 10,000,000.

Current official law controls clonazepam while permitting regulated prescription medical use in Germany.

The consolidated Drugs Rules, 1945, dated 1 July 2024 and released 19 September 2024, list Clonazepam at Schedule H entry 125. Clonazepam was already covered under Schedule H in CDSCO's 70th Drugs Technical Advisory Board minutes, and the 2006 CDSCO inclusion notification lists entry 125 as CLONAZEPAM. Rule 65(9) prohibits retail sale of Schedule H substances except on a Registered Medical Practitioner's prescription; Rule 97 requires the Schedule H/NDPS warning that the drug is to be sold by retail on the prescription of a Registered Medical Practitioner only. The NDPS Act Schedule lists clonazepam as psychotropic substance no. 38 (5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one). Section 8(c) prohibits production, manufacture, possession, sale, purchase, transport, use, consumption and related import/export except for medical or scientific purposes in the manner and extent provided by the Act, rules, orders and licence terms. Section 22 penalties for contravening those controls are: for small quantity, rigorous imprisonment up to one year or fine up to Rs. 10,000 or both; for greater than small but less than commercial quantity, rigorous imprisonment up to ten years and fine up to Rs. 1 lakh; for commercial quantity, rigorous imprisonment of 10–20 years and fine of Rs. 1–2 lakh, with the court able to impose a higher fine for recorded reasons. The official NDPS Rules separately require sale, purchase, consumption or use of psychotropic substances to comply with the Drugs and Cosmetics Rules (Rule 65A); Rule 66 allows an otherwise unauthorised individual to possess a reasonable quantity for genuine medical requirements, capped at 100 dosage units for personal medical use, or more than 100 and not exceeding 300 dosage units for personal long-term medical use when specifically prescribed by a Registered Medical Practitioner. The official CBN quantity table lists serial 189 CLONAZEPAM as 5 g small quantity and 100 g commercial quantity. Section 27 consumption penalties exist separately, but clonazepam's inclusion within the special substance class in section 27(a) is not established; accordingly, no clonazepam-specific consumption penalty is stated. Exact liability depends on conduct, amount, formulation, authorisation, prescription and facts.

The ordinance lists clonazepam as controlled; Clonex preparations containing clonazepam are prescription-only under the Ministry of Health leaflet.

The Opiumwet, effective 9 July 2026, lists clonazepam in List II with a dash for alternative names and further description. Article 3 prohibits bringing a List II substance into or out of the Netherlands, preparing, processing, selling, delivering, supplying, transporting, possessing or manufacturing it. Opiumwetbesluit Annex 1(b) includes the substances on List II (except hashish) in the medicines eligible for the prescription framework; Article 3 requires each opiumwetmiddel to be prescribed on a separate prescription, and Article 4 requires established pharmacists to dispense only on the specified prescription, subject to its narrow emergency exception. The Opiumwetbesluit Article 8 exception list does not name clonazepam, so the special dispensing and record rules are not removed for clonazepam preparations. Opiumwet Article 5 preserves limited lawful medical channels, including pharmacists acting in normal professional practice and a person who needs the substance for personal medical use and obtained it lawfully. The current Geneesmiddelenwet defines a UR-geneesmiddel as a medicine that may be supplied only on prescription and Article 61(9) bars a pharmacist from supplying one without a prescription except in an emergency where misuse risk is sufficiently excluded. The official CBG SmPC identifies authorized Clonazepam TZF 0.5 mg and 2 mg tablets (RVG 129008 and 129009), each containing clonazepam, and gives epilepsy indications; its official patient leaflet says the medicine is prescribed only to the individual patient. Article 11 sets the relevant intentional List II penalties: up to two years or a fifth-category fine for Article 3(B)-(D), up to six years or a fifth-category fine for professional/business Article 3(B) conduct, up to four years or a fifth-category fine for Article 3(A) import/export, and up to six years or a fifth-category fine for a large quantity. Article 11(7) removes the Article 11(2) and (4) penalty provisions for a small List II amount intended for personal use (other than hemp/hashish); this is not a general authorization.

The current consolidated schedule identifies clonazepam in List III and attributes its introduction to Government Resolution No. 78 of 4 February 2013. Federal Law No. 3-FZ permits List III circulation for medical and specified statutory purposes, and requires prescription dispensing for List III substances. Ministry of Health Order No. 1094n specifies prescription form 148-1/u-88 for psychotropic List III medicines. Resolution No. 1002 gives clonazepam significant, large and especially large quantities of 0.2 g, 1 g and 200 g for Criminal Code Articles 228, 228.1, 229 and 229.1. Unauthorized possession or other conduct can therefore have administrative or criminal consequences depending on the charged conduct and quantity; the penalty ranges below are statutory maxima/ranges, not a case-specific outcome.

The Health Ministry guide lists Klonazepam among benzodiazepines and states that sedative and hypnotic medicines are required to be prescribed on green or red prescriptions. The official Police 2010 report separately names clonazepam among psychoactive active ingredients subject to green prescription. The official Police 2021 report records that red- and green-prescription medicines entered the Electronic Coloured Prescription System on 17 March 2017. The Ministry of Justice Penal Code text supplies the applicable unlicensed-conduct and personal-use penalties.

Current official law controls clonazepam while permitting regulated prescription medical use in United Kingdom.